Shares of Axsome Therapeutics plunged 8.6% to $132.00 on November 2, even after the company posted third-quarter results that topped Wall Street estimates on both revenue and earnings — a classic "beat and sell" that signals investors are worried about what comes next, not what just happened. Axsome Beats on Every Metric Yet Drops 8.6% — Is Wall Street Losing Faith in the Growth-at-Any-Cost Playbook?
Shares of Axsome Therapeutics tumbled 8.6% to $132.00 on November 2 despite the biotech beating analyst estimates on both revenue and earnings — a sharp signal that investors are demanding more than headline beats from a company burning cash to chase blockbuster status.
Axsome posted Q3 revenue of $259.7 million, up 51.9% year-over-year, topping forecasts by roughly $10 million, while its loss of $0.25 per share was far narrower than the $0.58 loss analysts expected. Broader indexes traded higher, isolating this as a company-specific reaction.
• Spending Over $200 Million a Quarter to Sell Drugs
Selling, general, and administrative expenses — the cost of salespeople, marketing, and corporate overhead — rose to $203.1 million, up from $150.2 million a year earlier. That means for every dollar of net product revenue, Axsome spent roughly 78 cents just on commercialization. The net loss narrowed to $12.9 million from $47.2 million a year ago , but the path to actual profitability still depends on revenue growing much faster than expenses — a gap that hasn't widened convincingly.
• Discounts Set to Rise, Squeezing What Axsome Actually Keeps
Gross-to-net discounts — the difference between a drug's list price and what the company actually collects after rebates — improved to the mid-to-high 40% range for its lead depression drug and high 40s for its sleep disorder drug, but management warned both would "increase slightly in Q4 due to typical seasonality."
Meanwhile, the company's migraine treatment carries discounts in the mid-80% range , meaning Axsome keeps only about 15 cents on every gross dollar for that product.
• A $1 Billion Run Rate Sounds Great — Until Growth Math Gets Harder
CEO Herriot Tabuteau said Axsome "surpassed a one-billion-dollar annual run rate." But sustaining 52% growth from a billion-dollar base requires adding roughly $500 million in new sales annually. Sequential new-patient growth for the lead drug already decelerated from 26% in Q2 to 21% in Q3 , hinting at a natural slowdown as the easy gains are captured.
• Analysts Still Love the Stock — for Now
Wall Street's 21 analysts hold a consensus "Strong Buy" with an average price target of $285.42 — roughly 116% above today's close , with the lowest target at $246. The company says its $314 million cash balance should fund operations through cash-flow breakeven. But several firms, including Deutsche Bank and Morgan Stanley, have already begun trimming targets , suggesting even bulls are recalibrating expectations. At $132, the stock prices in meaningful doubt that Axsome can turn its revenue momentum into real earnings before the money runs thin.